Stock BCDA BIOCARDIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
0.375 USD -0.32% Intraday chart for BioCardia, Inc. -1.19% -43.54%
01/05 BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial CI
30/04 Transcript : BioCardia, Inc. - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
AQ
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial
CI
Transcript : BioCardia, Inc. - Special Call
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
CI
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
AQ
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure
CI
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
AQ
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
CI
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
AQ
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
CI
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding
CI
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
AQ
BioCardia, Inc.  Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
CI
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
AQ
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCDA Stock
  4. News BioCardia, Inc.